Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 13

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 13
---
® Molecular Tags,                                                                         
 which are short non-biologic DNA taggants produced by the Company’s LineaDNA platform, provide     
 a methodology to authenticate goods within large and complex supply chains with a focus on cotton, 
 nutraceuticals and other products.                                                                 |

| · | SigNify® portable DNA                                                                                                         
 readers and SigNify consumable reagent test kits provide definitive real-time authentication of the Company’s DNA tags in the 
 field.                                                                                                                        |

| · | fiberTyping® and other                                                                                                       
 product genotyping services use PCR-based DNA detection to determine a cotton species or cultivar, via a product’s naturally 
 occurring DNA sequence for the purposes of product provenance authentication.                                                |

| · | Isotopic analysis testing                                                                                                     
 services, provided in partnership with third-party labs, use cotton’s carbon, hydrogen and oxygen elements to indicate origin 
 of its fiber through finished goods.                                                                                          |

To date, our largest commercial application for
our DNA Tagging and Security Products and Services is in the tracking and provenance authentication of cotton.

<div align='center'>5</div>

On December 17, 2024, the Company announced it is exploring the potentialclosure or divestiture of its DNA Tagging and
Security Products and Services business segment. No assurance can be given that a closure or divestiture will be completed.

Recent Developments

Warrant Exercises

In December of 2024 and January of 2025, an
aggregate of 3,643,164 of our May 2024 Series A Warrants (as defined below) to purchase shares of our Common Stock were exercised, with
421,164 of such May 2024 Series A Warrants being exercised at a purchase price of $0.19 per share, and 3,222,000 of such May 2024 Series
A Warrants being exercised at a purchase price of $0.20 per share, for aggregate total proceeds of approximately $729,000.

Company’s Announcement of Exploration of Closure or Divestiture of Business Segment and Changes to Management Team

On December 17, 2024, that Company announced its intention to restructure its operations to prioritize itsTherapeutic DNA Production
Services and is exploring the closure or divestiture of its DNA Tagging and Security Products and Services business segment. In association
with the potential closure or divestiture, the Company is targeting a 15% reduction of its operating expenses in fiscal year 202